Judging a Protein by More Than Its Name: GSK-3

  title={Judging a Protein by More Than Its Name: GSK-3},
  author={James R. Woodgett},
  journal={Science's STKE},
  pages={re12 - re12}
  • J. Woodgett
  • Published 18 September 2001
  • Biology
  • Science's STKE
As knowledge of cellular signal transduction has accumulated, general truisms have emerged, including the notion that signaling proteins are usually activated by stimuli and that they, in turn, mediate the actions of specific agonists. Glycogen synthase kinase-3 (GSK-3) is an unusual protein-serine kinase that bucks these conventions. This evolutionarily conserved protein kinase is active in resting cells and is inhibited in response to activation of several distinct pathways, including those… 
GSK-3: tricks of the trade for a multi-tasking kinase
Since increased GSK-3 activity may be linked to pathology in diseases such as Alzheimer's disease and non-insulin-dependent diabetes mellitus, several new G SKS-3 inhibitors, such as the aloisines, the paullones and the maleimides, have been developed and hold promise as therapeutic agents.
GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs.
It is shown that the stimulatory effect of yeast Rcn1 involves phosphorylation of a conserved serine residue by Mck1, a member of the GSK-3 family of protein kinases, which may contribute to a positive feedback loop involving calcineurin-dependent up-regulation of RCN expression.
Glycogen synthase kinase 3ß functions as a positive effector in the WNK signaling pathway
Results suggest that GSK3ß/Sgg functions as a positive effector in the WNK signaling pathway, which is involved in neural specification downstream of WNK.
Is Glycogen Synthase Kinase-3β an Ultraconserved Kernel Enzyme?
Evidence is provided that GSK3β is an ultraconserved protein which would suggest that the enzyme qualify to be a kernel protein in the sense that life as the authors know it depends on conserved molecular entities to provide the essential functionality to an organism.
Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging
The structure, function, expression levels, and ligand-binding properties of GSK-3 and its connection to various diseases are reviewed and a rational perspective and possible route to selective and effective G SKS-3 inhibitors is discussed.
Two Putative BIN2 Substrates Are Nuclear Components of Brassinosteroid Signaling1
It is proposed that BES1/BZR1 are two nuclear components of BR signaling that are negatively regulated by BIN2 through a phosphorylation-initiated process.
Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer
This is the first report describing autophagy induction due to GSK-3 inhibition in renal cancer cells, and potent antiproliferative activity of 9-ING-41, a maleimide-based G SKS-3 inhibitor is shown.


Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death.
It is shown that the novel potent and selective small-molecule inhibitors of GSK-3, SB-415286 and SB-216763, protect both central and peripheral nervous system neurones in culture from death induced by reduced PI 3-kinase pathway activity.
Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells.
Expression of immediate-early genes involving the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive element (TRE) is modulated by post-translational modification of pre-existing activator
Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death
The data provide clear pharmacological and biochemical evidence that selective inhibition of the endogenous pool of GSK‐3 activity in primary neurones is sufficient to prevent death, implicating G SK‐3 as a physiologically relevant principal regulatory target of the PI’3‐kinase/PKB neuronal survival pathway.
Suppression of Glycogen Synthase Kinase Activity Is Not Sufficient for Leukemia Enhancer Factor-1 Activation*
Investigation of the effect of an activated Akt on the accumulation of cytosolic β-catenin and LEF-1-dependent transcription suggests that inhibition of GSK kinase activity is not sufficient for activation of LEf-1 but may facilitate the activation by reducing the interaction of Gsk for Axin.
Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy.
Two forms of GSK-3 function to decrease the DNA-binding activity as well as the transcriptional activation elicited by c-Jun in vivo, and the products of the sgg gene can also function as negative regulators of Jun/AP-1.
Interaction among Gsk-3, Gbp, Axin, and APC in Xenopus Axis Specification
GBP functions by preventing the GSK-3–mediated phosphorylation of a protein substrate without eliminating its catalytic activity, and it is shown that APC is impinging upon the canonical Wnt pathway in this model system.